Outset Medical, Inc. (NASDAQ:OM) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have received a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.00.

OM has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research note on Friday, March 27th. TD Cowen restated a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Finally, Wall Street Zen cut Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th.

Insider Buying and Selling

In other news, CFO Renee Gaeta sold 17,672 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total value of $87,299.68. Following the completion of the sale, the chief financial officer directly owned 113,753 shares in the company, valued at approximately $561,939.82. The trade was a 13.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 25,337 shares of company stock worth $115,660 in the last 90 days. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. BML Capital Management LLC boosted its position in shares of Outset Medical by 250.2% in the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after acquiring an additional 1,359,021 shares during the period. Alyeska Investment Group L.P. increased its position in Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after acquiring an additional 150,000 shares during the period. Ensign Peak Advisors Inc raised its stake in Outset Medical by 71.8% during the 4th quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock valued at $2,078,000 after purchasing an additional 234,082 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Outset Medical by 34.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock valued at $1,886,000 after purchasing an additional 131,381 shares during the period. Finally, Millennium Management LLC boosted its holdings in Outset Medical by 165.8% in the 3rd quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after purchasing an additional 262,874 shares during the period.

Outset Medical Stock Down 2.5%

Shares of Outset Medical stock opened at $4.76 on Wednesday. The firm has a market cap of $88.25 million, a price-to-earnings ratio of -1.14 and a beta of 1.95. The stock has a 50-day simple moving average of $4.41 and a 200-day simple moving average of $4.18. Outset Medical has a 52-week low of $3.00 and a 52-week high of $21.36. The company has a debt-to-equity ratio of 0.87, a current ratio of 6.29 and a quick ratio of 4.97.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.04). The business had revenue of $27.86 million for the quarter, compared to the consensus estimate of $28.90 million. Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. On average, equities research analysts expect that Outset Medical will post -3.82 earnings per share for the current fiscal year.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.